Legend Biotech Corp (LEGN)
About Legend Biotech Corp
Legend Biotech Corp is a clinical-stage biopharmaceutical company. It is engaged in the discovery and development of novel cell therapies for oncology and other indications. The firm's product candidate, LCAR-B38M/JNJ-4528, is a chimeric antigen receptor, or CAR, T cell therapy for the treatment of multiple myeloma. Geographically, the company generates a majority of its revenue from the United States of America. The company generates revenue from License and Collaboration revenue.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Market cap
- $6.1B
15-minute delayed · data by Polygon.io
Past year · hover for prices
52-week range
- Market cap
- $6.1B
- Shares outstanding
- 272.7M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Jun 5, 2020
Legend Biotech Corp (LEGN) Stock Price
- Trading 50% below its 52-week high.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review Legend Biotech Corp.
Write a review
News about Legend Biotech Corp
News & sentiment via Polygon.io
Legend Biotech Corp: frequently asked questions
Is Legend Biotech Corp an American company?
Legend Biotech Corp is a US-based company headquartered in Somerset, New Jersey, listed in the americancompanies.com directory of American companies. Its American-origin credentials have not yet been independently verified.
Where is Legend Biotech Corp headquartered?
Legend Biotech Corp is headquartered in Somerset, New Jersey, United States.
Is Legend Biotech Corp publicly traded?
Yes — Legend Biotech Corp is a publicly traded company. Its stock trades under the ticker symbol LEGN on the NASDAQ.
What does Legend Biotech Corp do?
Legend Biotech Corp is an American Pharmaceuticals company in the Health & Beauty sector.
